The DFU information was released with the CR presentation back in April (slides 17-19): https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02652273-7NSCRSUGSJJKGVONAOHJ1S31OE/pdf?access_token=0007YUZeQM9jdt0x5ryaOwTUcoAr
What is notable is the inclusion of more preclinical data demonstrating Cymerus MSCs reduction of heterogeneity compared to tissue-derived MSCs. Heterogeneity is a major hurdle to the commercialisation of MSC therapies. As the FDA noted in the ODAC briefing document for Rem-L, in the absence of outstanding results from a well-controlled clinical trial, the therapy at the very least needs to have a mechanism of action (MOA) consistent with what is observed in laboratory testing. If the underlying treatment is not consistent on a batch-to-batch basis, that makes it difficult to achieve. Fortunately, a single blood donation is the foundation for 21 million clinical doses of Cymerus MSCs, greatly improving the probability that the clinical MOA will closely match what is expected.
- Forums
- ASX - By Stock
- CYP
- Ann: Investor Webinar Presentation
Ann: Investor Webinar Presentation, page-9
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.89M |
Open | High | Low | Value | Volume |
30.5¢ | 30.5¢ | 30.0¢ | $13.45K | 44.77K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 27229 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 6000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 27229 | 0.300 |
1 | 40000 | 0.295 |
1 | 10000 | 0.290 |
1 | 7000 | 0.280 |
1 | 1854 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 33218 | 3 |
0.330 | 2000 | 1 |
0.340 | 18523 | 2 |
0.345 | 34372 | 4 |
0.350 | 88892 | 1 |
Last trade - 15.56pm 07/06/2024 (20 minute delay) ? |
|
|||||
Last
30.0¢ |
  |
Change
0.000 ( 1.64 %) |
|||
Open | High | Low | Volume | ||
31.0¢ | 31.0¢ | 30.0¢ | 16729 | ||
Last updated 13.34pm 07/06/2024 ? |
Featured News
CYP (ASX) Chart |